Involved-Field Radiation Therapy

RADIATION4 trials

Sponsors

Children's Oncology Group, Yonsei University, NRG Oncology

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Childhood Lymphocyte-Depleted Classical Hodgkin LymphomaChildhood Mixed Cellularity Classical Hodgkin LymphomaChildhood Nodular Lymphocyte Predominant Hodgkin LymphomaChildhood Nodular Sclerosis Classical Hodgkin LymphomaMedulloblastomaMetastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma

Phase 3

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

CompletedNCT00025259

Children's Oncology GroupChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma +5

Start: 2002-09-30Updated: 2017-04-12

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

CompletedNCT00085735

Children's Oncology GroupMedulloblastoma

Start: 2004-04-30End: 2024-12-31Updated: 2025-01-14

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

RecruitingNCT06500481

NRG OncologyAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma +2

Start: 2025-03-04End: 2028-07-31Target: 115Updated: 2026-04-03

Unknown Phase

The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial

CompletedNCT02135523

Yonsei UniversityOvarian Cancer (Epithelial)

Start: 2014-02-06End: 2018-01-08Updated: 2018-05-17

Related Papers

An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.

2025-10-241 citations

Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-Risk Hodgkin Lymphoma

Blood2023-11-021 citations

Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma

Blood2023-11-02

Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Blood2022-11-152 citations

Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.

2022-01-0120 citations

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Blood2021-10-2014 citations

Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma

Journal of Clinical Oncology2021-06-10180 citations

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Blood2020-12-1926 citations

Primary mediastinal large B‐cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy

British Journal of Haematology2020-05-296 citations

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

Blood Advances2017-04-2432 citations